[
  {
    "ts": "2025-08-04T21:48:11+00:00",
    "headline": "Stocks to Watch Monday: Palantir, Hims & Hers, Vertex, Tesla",
    "summary": "↗️ Palantir (PLTR): The data-software company's stock rose 4% postmarket after earnings showed higher profit and revenue. Palantir, which also boosted its full-year outlook, had gained 4.1% during regular trading hours.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-08-04-2025/card/stocks-to-watch-monday-commscope-boeing-berkshire-amazon-jQ9aqcCBoJicpF2QgdPG?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "a4f74e06-a6c4-312d-8a34-79d639cdd5f7",
      "content": {
        "id": "a4f74e06-a6c4-312d-8a34-79d639cdd5f7",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Palantir, Hims & Hers, Vertex, Tesla",
        "description": "",
        "summary": "↗️ Palantir (PLTR): The data-software company's stock rose 4% postmarket after earnings showed higher profit and revenue. Palantir, which also boosted its full-year outlook, had gained 4.1% during regular trading hours.",
        "pubDate": "2025-08-04T21:48:11Z",
        "displayTime": "2025-08-04T21:48:11Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a4f74e06-a6c4-312d-8a34-79d639cdd5f7/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/de72c6c058ca14744b6f32abeec30cf8",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jgjLVBYPQBibJg5HU0xuig--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/de72c6c058ca14744b6f32abeec30cf8.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9qlr6QYDQhriWuPDKHmVUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/de72c6c058ca14744b6f32abeec30cf8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-08-04-2025/card/stocks-to-watch-monday-commscope-boeing-berkshire-amazon-jQ9aqcCBoJicpF2QgdPG?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IDXX"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "BA"
            },
            {
              "symbol": "COMM"
            },
            {
              "symbol": "APH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T21:30:01+00:00",
    "headline": "Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics",
    "summary": "While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finance.yahoo.com/news/compared-estimates-vertex-vrtx-q2-213001405.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "82ffcc77-888c-3382-9cb2-3098b00889f5",
      "content": {
        "id": "82ffcc77-888c-3382-9cb2-3098b00889f5",
        "contentType": "STORY",
        "title": "Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics",
        "description": "",
        "summary": "While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
        "pubDate": "2025-08-04T21:30:01Z",
        "displayTime": "2025-08-04T21:30:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PIdvgNQlfpuBODSIZCqYyg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sAMTWSt0tSP35kyVmwadNw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/compared-estimates-vertex-vrtx-q2-213001405.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/compared-estimates-vertex-vrtx-q2-213001405.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T21:15:03+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates",
    "summary": "Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-surpasses-q2-211503307.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "56249afa-d2a3-3436-a7f9-eb529d1e124b",
      "content": {
        "id": "56249afa-d2a3-3436-a7f9-eb529d1e124b",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates",
        "description": "",
        "summary": "Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
        "pubDate": "2025-08-04T21:15:03Z",
        "displayTime": "2025-08-04T21:15:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PIdvgNQlfpuBODSIZCqYyg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sAMTWSt0tSP35kyVmwadNw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-surpasses-q2-211503307.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-surpasses-q2-211503307.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T21:13:00+00:00",
    "headline": "Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings",
    "summary": "The biotechnology company’s stock fell in post-market trading, after saying it would not progress a next-generation pain treatment into advanced testing.",
    "url": "https://www.wsj.com/business/earnings/vertex-stock-falls-after-pain-drug-setback-despite-stronger-earnings-192df986?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "91a94d0b-28d1-380f-b0fe-0beaf12c09d7",
      "content": {
        "id": "91a94d0b-28d1-380f-b0fe-0beaf12c09d7",
        "contentType": "STORY",
        "title": "Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings",
        "description": "",
        "summary": "The biotechnology company’s stock fell in post-market trading, after saying it would not progress a next-generation pain treatment into advanced testing.",
        "pubDate": "2025-08-04T21:13:00Z",
        "displayTime": "2025-08-04T21:13:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/91a94d0b-28d1-380f-b0fe-0beaf12c09d7/vertex-stock-falls-after.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6d0ca585cc2f68b12873a64c4a0c642f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g5A8K6x5WJKfk25blt3ZNg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6d0ca585cc2f68b12873a64c4a0c642f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Kq_tc_IEE9ckDpMP4iLVyw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6d0ca585cc2f68b12873a64c4a0c642f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/earnings/vertex-stock-falls-after-pain-drug-setback-despite-stronger-earnings-192df986?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T20:21:18+00:00",
    "headline": "Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full year’s revenue to be around $11.93 billion, close to analysts’ estimates. Its non-GAAP profit of $4.52 per share was 6.3% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-nasdaq-vrtx-q2-202118562.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "7d3da349-0d39-3a22-b30a-9eb72498be24",
      "content": {
        "id": "7d3da349-0d39-3a22-b30a-9eb72498be24",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%",
        "description": "",
        "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full year’s revenue to be around $11.93 billion, close to analysts’ estimates. Its non-GAAP profit of $4.52 per share was 6.3% above analysts’ consensus estimates.",
        "pubDate": "2025-08-04T20:21:18Z",
        "displayTime": "2025-08-04T20:21:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VRTX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l6Y31wu10RiElUns.3mORA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qe_uhCRKlCGgByoENi3GZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-nasdaq-vrtx-q2-202118562.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-nasdaq-vrtx-q2-202118562.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T20:16:53+00:00",
    "headline": "Vertex: Q2 Earnings Snapshot",
    "summary": "The Boston-based company said it had net income of $3.99 per share. Earnings, adjusted for one-time gains and costs, were $4.52 per share. The results beat Wall Street expectations.",
    "url": "https://finance.yahoo.com/news/vertex-q2-earnings-snapshot-201653609.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "d9347660-2222-336b-98e6-2b39f4bff7c8",
      "content": {
        "id": "d9347660-2222-336b-98e6-2b39f4bff7c8",
        "contentType": "STORY",
        "title": "Vertex: Q2 Earnings Snapshot",
        "description": "",
        "summary": "The Boston-based company said it had net income of $3.99 per share. Earnings, adjusted for one-time gains and costs, were $4.52 per share. The results beat Wall Street expectations.",
        "pubDate": "2025-08-04T20:16:53Z",
        "displayTime": "2025-08-04T20:16:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-q2-earnings-snapshot-201653609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-q2-earnings-snapshot-201653609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T20:15:00+00:00",
    "headline": "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results",
    "summary": "-CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth- -Clinical trial ongoing for CTX310™, targeting ANGPTL3, with preliminary data showing dose-dependent reductions of up to 82% in triglycerides (TG) and 86% in low-density lipoprotein (LDL), and a well-tolerated safety profile; data presentation anticipated at a medical mee",
    "url": "https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-201500262.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c60b1436-a6b7-3b94-b979-e3f270574076",
      "content": {
        "id": "c60b1436-a6b7-3b94-b979-e3f270574076",
        "contentType": "STORY",
        "title": "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results",
        "description": "",
        "summary": "-CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth- -Clinical trial ongoing for CTX310™, targeting ANGPTL3, with preliminary data showing dose-dependent reductions of up to 82% in triglycerides (TG) and 86% in low-density lipoprotein (LDL), and a well-tolerated safety profile; data presentation anticipated at a medical mee",
        "pubDate": "2025-08-04T20:15:00Z",
        "displayTime": "2025-08-04T20:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/1aff8de1b43a5c2c983997aa98d58aad",
          "originalWidth": 1800,
          "originalHeight": 1957,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mnPsJEczvucHirpNfZ3Hpg--~B/aD0xOTU3O3c9MTgwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/1aff8de1b43a5c2c983997aa98d58aad.cf.webp",
              "width": 1800,
              "height": 1957,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8jC0wMX28ixyv6Mj1oYr_A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/1aff8de1b43a5c2c983997aa98d58aad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-201500262.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-201500262.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T20:01:00+00:00",
    "headline": "Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain",
    "summary": "BOSTON, August 04, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of th",
    "url": "https://finance.yahoo.com/news/vertex-announces-results-phase-2-200100860.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "fa71f14f-93c1-3352-9678-1c4cb444604c",
      "content": {
        "id": "fa71f14f-93c1-3352-9678-1c4cb444604c",
        "contentType": "STORY",
        "title": "Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain",
        "description": "",
        "summary": "BOSTON, August 04, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of th",
        "pubDate": "2025-08-04T20:01:00Z",
        "displayTime": "2025-08-04T20:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/1fabb83e52af290612145b85c092676d",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YQjn9Pm5RLK2K4vWsq1dUQ--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1fabb83e52af290612145b85c092676d.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IN.ScurEv8kz_tj5AsKAzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1fabb83e52af290612145b85c092676d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-announces-results-phase-2-200100860.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-announces-results-phase-2-200100860.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "META"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-04T20:01:00+00:00",
    "headline": "Vertex Reports Second Quarter 2025 Financial Results",
    "summary": "BOSTON, August 04, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2025, and reiterated full year 2025 financial guidance.",
    "url": "https://finance.yahoo.com/news/vertex-reports-second-quarter-2025-200100732.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "aafff658-d480-3a20-a210-fc9f7e9eae81",
      "content": {
        "id": "aafff658-d480-3a20-a210-fc9f7e9eae81",
        "contentType": "STORY",
        "title": "Vertex Reports Second Quarter 2025 Financial Results",
        "description": "",
        "summary": "BOSTON, August 04, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2025, and reiterated full year 2025 financial guidance.",
        "pubDate": "2025-08-04T20:01:00Z",
        "displayTime": "2025-08-04T20:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/e96aed4b911f5c0ddf3f657e5bdb48be",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TK_gZbvTFGNAlrAcX4Fn3Q--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e96aed4b911f5c0ddf3f657e5bdb48be.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1ONI6YR3qwP07AtMcf9w5A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e96aed4b911f5c0ddf3f657e5bdb48be.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-reports-second-quarter-2025-200100732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-reports-second-quarter-2025-200100732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]